Antradienį Vyriausybės kanclerė Giedrė Balčytytė susitiko su organizacijos „Medicine for Europe“ generaliniu direktoriumi Adrianu van den Hovenu, su kuriuo aptarė Europoje ir pasaulyje pastaruoju metu stebimus vaistų tiekimo sutrikimus ir būtinybę užtikrinti vaistų prieinamumą pacientams. Kaip pabrėžė kanclerė, Lietuvos Vyriausybė laiko prioritetu vaistų įperkamumą gyventojams, todėl ir toliau aktyviai dalyvaus vaistų politikoje ir stebės situaciją vaistų rinkoje.
We understand the importance of stimulating competition in the pharmaceutical market for budget sustainability. However, EURIPID and other authorities have clearly indicated that ERP should not be applied in combination with generic reference pricing policies because this distorts the market and undermines the commercial viability of supplying the market.
The EU pharmaceutical strategy aims to improve accessibility, affordability and sustainability of medicines for European patients and healthcare systems with a focus on the Central and Eastern European (CEE) region.
Generic, Biosimilar and Value-Added Medicines play an essential role in the sustainability of healthcare systems by bringing competition to the market, providing healthcare systems budget relief and enabling the reinvestments of savings into greater access to medicines.
The EU pharmaceutical strategy aims to improve accessibility, affordability and sustainability of medicines for European patients and healthcare systems with a focus on the Central and Eastern European (CEE) region.
Generic, Biosimilar and Value-Added Medicines play an essential role in the sustainability of healthcare systems by bringing competition to the market, providing healthcare systems budget relief and enabling the reinvestments of savings into greater access to medicines.
The EU pharmaceutical strategy aims to improve accessibility, affordability and sustainability of medicines for European patients and healthcare systems with a focus on the Central and Eastern European (CEE) region.
Generic, Biosimilar and Value-Added Medicines play an essential role in the sustainability of healthcare systems by bringing competition to the market, providing healthcare systems budget relief and enabling the reinvestments of savings into greater access to medicines.
At the Ukraine Recovery Conference in London, the European Business Association and Medicines for Europe signed a Memorandum of Agreement to accelerate Ukraine’s integration into the EU pharmaceutical market.
Malta agrees with the European Commission’s legislative proposals to improve access to medicines and to establish a pharmaceutical common market in the European Union. Talks between Malta’s deputy Prime Minister and Health Minister, Chris Fearne and the EU Commissioner for Health and Food Safety, Stella Kyriakides, focused on the challenges of small markets, such as that of Malta.
Shortages of medicines within the EU and the improved access to innovative medication across the Union, particularly in small markets such as Malta, were the main focus of discussions between Deputy Prime Minister and Minister for Health Chris Fearne and European Commissioner for Health and Food Safety, Stella Kyriakides, during her official visit to Malta.
Medicine shortages within the EU and improved access to innovative medication across the union, particularly in small markets such as Malta, were the main focus of discussions between Health Minister Chris Fearne and European Health Commissioner Stella Kyriakides.